Literature DB >> 10348780

Rifampin and rifabutin resistance mechanism in Helicobacter pylori.

M Heep1, D Beck, E Bayerdörffer, N Lehn.   

Abstract

Eighty-one clinical isolates of Helicobacter pylori showed no resistance to rifampin (MIC range, 0.032 to 2 microg/ml; MIC at which 50% of isolates are inhibited [MIC50], 0.25 microg/ml). The MIC50 of rifabutin was 0.008 microg/ml (n = 16). All resistant laboratory mutants of H. pylori ATCC 43504 showed amino acid exchanges in codons 524 to 545 or codon 585 of the rpoB gene, corresponding to the gene sequences from Mycobacterium tuberculosis and Escherichia coli.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10348780      PMCID： PMC89306          DOI： 10.1128/AAC.43.6.1497

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new mutations and notes on population genetics.

Authors:  O Nolte
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  The complete genome sequence of the gastric pathogen Helicobacter pylori.

Authors:  J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

3.  Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan.

Authors:  H Ohno; H Koga; S Kohno; T Tashiro; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Treatment of antibiotic-resistant Helicobacter pylori.

Authors:  F Perri; V Festa; A Andriulli
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

5.  Molecular evolution of rifampicin resistance in Streptococcus pneumoniae.

Authors:  M Enright; P Zawadski; P Pickerill; C G Dowson
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

Review 6.  Antimicrobial activity of rifabutin.

Authors:  C M Kunin
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

7.  Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the beta subunit of Escherichia coli RNA polymerase.

Authors:  K Severinov; M Soushko; A Goldfarb; V Nikiforov
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

8.  Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability.

Authors:  F J Abadi; P E Carter; P Cash; T H Pennington
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa.

Authors:  Y C Yee; B Kisslinger; V L Yu; D J Jin
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

10.  Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.

Authors:  D L Williams; L Spring; L Collins; L P Miller; L B Heifets; P R Gangadharam; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  58 in total

1.  Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations.

Authors:  H Hu; K Ochi
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

2.  Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.

Authors:  M Heep; U Rieger; D Beck; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins.

Authors:  M Heep; S Odenbreit; D Beck; J Decker; E Prohaska; U Rieger; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

4.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 5.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

6.  Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

Authors:  Sander Veldhuyzen van Zanten; Snehal Desai; Linda Best; Geraldine Cooper-Lesins; Dickran Malatjalian; David Haldane; Kevork Peltekian
Journal:  Can J Gastroenterol       Date:  2010-05       Impact factor: 3.522

7.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

8.  Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease.

Authors:  Vineet Ahuja; Vikram Bhatia; S Dattagupta; Akshay Raizada; Mahesh Prakash Sharma
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 9.  Mode of action of microbial bioactive metabolites.

Authors:  V Bethal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 10.  Basis for the management of drug-resistant Helicobacter pylori infection.

Authors:  Francis Mégraud
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.